Babak Litkouhi

Supplemental Figure 1: Kaplan Meier Survival Curves by TCGA Molecular Subtype

Supplemental Figure 1: Kaplan Meier Survival Curves by TCGA Molecular Subtype

Supplemental Figure 2: Schoenfeld’s test of proportional hazards for multivariate Cox analysis including CINSARC and EcoTyper Classifiers.

Supplemental Figure 2: Schoenfeld’s test of proportional hazards for multivariate Cox analysis including CINSARC and EcoTyper Classifiers.

Supplemental Figure 3: EERI Values in TCGA Subtypes. A) The Stanford-EEC cohort and subgroups. B) The TCGA-UCEC cohort and subgroups. P-values generated by Whitney-Mann U test. Error bars represent 95% confidence intervals.

Supplemental Figure 3: EERI Values in TCGA Subtypes. A) The Stanford-EEC cohort and subgroups. B) The TCGA-UCEC cohort and subgroups. P-values generated by Whitney-Mann U test. Error bars represent 95% confidence intervals.

Supplemental Figure 4: Recurrence Free Survival stratified by EERI score for Stages I-IV disease in the TCGA-UCEC Cohort. Patients with EEC by stage at diagnosis. Patients were included with more than 1 year of follow-up and known endometri…

Supplemental Figure 4: Recurrence Free Survival stratified by EERI score for Stages I-IV disease in the TCGA-UCEC Cohort. Patients with EEC by stage at diagnosis. Patients were included with more than 1 year of follow-up and known endometri…

Supplemental Table 1: Genes used in EERI listed by prognostic impact.

Supplemental Table 1: Genes used in EERI listed by prognostic impact.

Supplemental Table 2: Clinical and Pathologic Variables of Cases and EERI False Negatives in both the Stanford-EEC cases and TCGA-UCEC recurrent patients

Supplemental Table 2: Clinical and Pathologic Variables of Cases and EERI False Negatives in both the Stanford-EEC cases and TCGA-UCEC recurrent patients

Supplemental Table 3: Clinical and Pathologic Variables of Controls and EERI False Positives in both the Stanford-EEC controls and TCGA-UCEC non-recurrent patients

Supplemental Table 3: Clinical and Pathologic Variables of Controls and EERI False Positives in both the Stanford-EEC controls and TCGA-UCEC non-recurrent patients

INTRODUCTION: Since the majority of patients are diagnosed at an advanced stage, ovarian cancer remains the most lethal gynecologic malignancy. There is no single biomarker with the sensitivity and specificity required for effective cancer …

Purpose: Uterine serous carcinoma (USC) is a rare and aggressive variant of endometrial cancer. Whole-exome sequencing (WES) studies have recently reported c-Myc gene amplification in a large number of USCs, suggesting c-Myc as a potential …